ASH 2018 | IciCLLe extension: ibrutinib and obinutuzumab for clears MRD in R/R CLL
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
The IciCLLe study (ISRCTN12695354), part of the Bloodwise Trials Acceleration Programme (TAP), explored the use of ibrutinib in chronic lymphocytic leukemia (CLL). As part of the study’s extension, relapsed/refractory patients were given ibrutinib with obinutuzumab. We spoke to Talha Munir, MBBS, of Leeds Teaching Hospitals NHS Trust, Leeds, UK, about this extension at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Munir highlights the improved MRD response rates for patients 1-year or more post-treatment, and explains how combining the two drugs worked better in the second-line setting.
Get great new content delivered to your inboxSign up